Plain-English translation of NCT05813626 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that helps your immune system recognize and fight cancer cells, combined with standard chemotherapy drugs. The study is for people with advanced nasopharyngeal cancer (cancer in the upper part of the throat behind the nose) who haven't had treatment yet. Researchers hope that giving this medication alongside chemotherapy before surgery will help shrink tumors and improve outcomes.
Advanced nasopharyngeal cancer is hard to treat and often comes back even after standard therapy. This trial exists because doctors believe that combining the medication with chemotherapy may help the immune system work harder against the cancer before surgery, potentially giving patients a better chance of staying cancer-free.
You will receive three cycles of chemotherapy (gemcitabine and ) plus the medication , with each cycle lasting 3 weeks. The medication and chemotherapy are given on the first day of each cycle and repeat every 3 weeks for a total of 9 weeks. During this time, you'll have regular blood tests and doctor visits to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Zhejiang Cancer Hospital
Enrollment target
~89 participants
Started
April 2023
Primary completion
August 2025
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in July 2026.